TrialLancet (London, England)2023

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.

Christopher W Ryan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.